AtriCure Inc. (NASDAQ:ATRC) shares saw strong trading volume on Monday . 291,520 shares were traded during trading, an increase of 50% from the previous session’s volume of 194,450 shares.The stock last traded at $13.87 and had previously closed at $13.54.

Several analysts recently weighed in on the company. Needham & Company LLC reissued a “buy” rating and set a $20.00 price target (down from $23.00) on shares of AtriCure in a report on Monday. Piper Jaffray Cos. reissued an “overweight” rating and set a $17.00 price target (down from $22.00) on shares of AtriCure in a report on Monday. Canaccord Genuity set a $21.00 price target on AtriCure and gave the stock a “buy” rating in a report on Saturday. JMP Securities set a $23.00 price target on AtriCure and gave the stock a “buy” rating in a report on Saturday. Finally, Stifel Nicolaus dropped their price target on AtriCure from $26.00 to $21.00 and set a “buy” rating for the company in a report on Friday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $21.25.

The stock’s market cap is $443.63 million. The firm’s 50 day moving average is $14.90 and its 200-day moving average is $15.84.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings results on Thursday, August 4th. The medical device company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.04. The firm earned $39.70 million during the quarter, compared to the consensus estimate of $39.84 million. During the same period in the previous year, the company posted ($0.18) EPS. The company’s revenue for the quarter was up 21.8% compared to the same quarter last year. On average, analysts forecast that AtriCure Inc. will post ($1.16) earnings per share for the current year.

Other hedge funds and institutional investors recently made changes to their positions in the company. RS Investment Management Co. LLC boosted its position in shares of AtriCure by 21.1% in the fourth quarter. RS Investment Management Co. LLC now owns 2,679,551 shares of the medical device company’s stock worth $60,129,000 after buying an additional 466,200 shares during the period. Wells Fargo & Company MN boosted its position in shares of AtriCure by 20.2% in the fourth quarter. Wells Fargo & Company MN now owns 659,070 shares of the medical device company’s stock worth $14,789,000 after buying an additional 110,890 shares during the period. Paradigm Capital Management Inc. NY boosted its position in shares of AtriCure by 108.3% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 247,525 shares of the medical device company’s stock worth $5,554,000 after buying an additional 128,700 shares during the period. Finally, Victory Capital Management Inc. boosted its position in shares of AtriCure by 15.3% in the fourth quarter. Victory Capital Management Inc. now owns 51,647 shares of the medical device company’s stock worth $1,159,000 after buying an additional 6,845 shares during the period.

AtriCure, Inc is a medical device company providing atrial fibrillation (Afib) solutions. The Company’s segment develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. The Company has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.